Results 31 to 40 of about 371,945 (298)

Have advances in medical therapy for ulcerative colitis impacted surgical treatment?

Annals of Gastroenterological Surgery, 2023
Aim The purpose of this study was to examine how the clinical characteristics, indications for surgery, and postoperative course of ulcerative colitis (UC) surgical patients changed before and after the introduction of biological agents. Methods Patients
Ryuichi Kuwahara, Hiroki Ikeuchi, Yuki Horio, Tomohiro Minagawa, Kurando Kusunoki, Motoi Uchino   +5 more
doaj   +1 more source

Imputation methods for serologic biomarkers in inflammatory bowel disease. [PDF]

Sci Rep
Serologic biomarkers have emerged as a powerful tool for the diagnosis of Inflammatory Bowel Disease (IBD) and the differentiation between subgroups of IBD.
Boodaghidizaji M, McGovern DPB, Li D.
europepmc   +2 more sources

Smoking in inflammatory bowel diseases: Good, bad or ugly?

, 2007
Smoking is an important environmental factor in inflammatory bowel disease (IBD), having different effects in ulcerative colitis (UC) and Crohn’s disease (CD).
Peter Laszlo Lakatos, Lakatos, Péter László, Tamas Szamosi, Szamosi, Tamás, Laszlo Lakatos, Lakatos, László   +5 more
core   +1 more source

Review of the safety with biologics in inflammatory bowel disease

Journal of IMIDs, 2022
Biologics have completely changed the treatment (and life) of patients with inflammatory bowel disease (IBD). After the first ones, anti-tumor necrosis factor (TNF) biologics, two new biologics, with other therapeutic targets, are now in routine use in ...
Andrea Pascual, Raquel Vicente, Eva Sierra, Santiago García-López   +3 more
doaj   +1 more source

Adalimumab Biosimilar in Pediatric Inflammatory Bowel Disease: A Retrospective Study from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD) [PDF]

Background: The utilization of anti-tumor necrosis factor-alpha (anti-TNF-alpha) biosimilars in inflammatory bowel disease (IBD) is constantly increasing. However, pediatric data are limited.
Francesco Graziano, Citrano, Michele, Orlando, Ambrogio, Pellegrino, Salvatore, Marco Ventimiglia, Sicilian Network For Inflammatory Bowel Disease, null, Dipasquale, Valeria, Cappello, Maria, Romano, Claudio, Anita Busacca, Ventimiglia, Marco, Graziano, Francesco, Valeria Dipasquale, Michele Citrano, Salvatore Pellegrino, Claudio Romano, Salvatore Accomando, Accomando, Salvatore, Maria Cappello, Busacca, Anita, Sicilian Network for Inflammatory Bowel Disease Sicilian Network for Inflammatory Bowel Disease, Ambrogio Orlando   +21 more
core   +1 more source

Systems biology in inflammatory bowel diseases [PDF]

, 2014
Purpose of review: Ulcerative colitis (UC) and Crohn’s Disease (CD) are the two predominant types of inflammatory bowel disease (IBD), affecting over 1.4 million individuals in the US.
Iliopoulos, D, Koukos, G, Polytarchou, C
core   +1 more source

Inflammatory Bowel Disease [PDF]

Annual Review of Immunology, 2010
Insights into inflammatory bowel disease (IBD) are advancing rapidly owing to immunologic investigations of a plethora of animal models of intestinal inflammation, ground-breaking advances in the interrogation of diseases that are inherited as complex genetic traits, and the development of culture-independent methods to define the composition of the ...
Arthur, Kaser, Sebastian, Zeissig, Richard S, Blumberg   +2 more
openaire   +5 more sources

Management of Anal Fistula with Crohn's Disease

Journal of the Anus, Rectum and Colon
Crohn's disease (CD) causes gastrointestinal symptoms (i.e., diarrhea and abdominal pain), systemic symptoms (i.e., fatigue, anemia, weight loss, and fever), and perianal fistulas that produce anal pain. Because of the frequent occurrence of diarrhea and
Shota Takano, Yasushi Nakamura, Kohei Tamaoka, Takafumi Yoshimoto, Yasue Irei, Yoriyuki Tsuji   +5 more
doaj   +1 more source

Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort

, 2014
BACKGROUND AND AIMS Limited data from large cohorts are available on tumor necrosis factor (TNF) antagonists (infliximab, adalimumab, certolizumab pegol) switch over time.
Safroneeva, Ekaterina, Safroneeva, E., Rogler, Gerhard, Schöpfer, Alain, Pittet, V., Vavricka, Stephan, Pittet, Valérie, Fournier, N., Hiroz, Philippe, Swiss Inflammatory Bowel Disease Cohort Study Group, Rogler, G., Fournier, Nicolas, Schoepfer, A.M., Swiss Inflammatory Bowel Diseases Cohort Study Group, The, Vavricka, S.R., Juillerat, Pascal, Hiroz, P., Vavricka, Stephan R, Schoepfer, Alain M   +18 more
core   +1 more source

OC-163 identification of inflammatory bowel disease (IBD) using field asymmetric ion mobility spectrometry (FAIMS) [PDF]

, 2012
Introduction Resident colonic bacteria, principally anaerobes and firmicutes, ferment undigested fibre. The resultant volatile organic compounds (VOCs) formed are dissolved in the faeces but also absorbed and excreted in the urine.
Thomas, M. G., Hetherington, E., Arasaradnam, Ramesh P., Ouaret, N., Covington, James A., Quraishi, M. N., Nwokolo, Chuka U., Bardhan, Karna Dev   +7 more
core   +1 more source